NCT03233932 - CKD-841 Pharmacokinetic/Pharmacodynamic Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

July 31, 2017

Study Completion Date

July 31, 2017

Conditions

Postmenopausal Disorder

Interventions

DRUG

LeuplinⓡInj

Investigational drug(=LeuplinⓡInj)is prescribed single injection dose by subcutaneous to 6 of randomized subjects once.

DRUG

CKD-841

Investigational drug(=CDK-841) is prescribed single injection dose by subcutaneous to 6 of randomized subjects once.

Trial Locations (1)

Severance Hospital, Seoul